News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
274,611 Results
Type
Article (14567)
Company Profile (281)
Press Release (259752)
Multimedia
Podcasts (65)
Webinars (12)
Section
Business (79695)
Career Advice (154)
Deals (13275)
Drug Delivery (38)
Drug Development (50584)
Employer Resources (31)
FDA (5781)
Job Trends (5154)
News (144767)
Policy (10059)
Tag
Academia (917)
Accelerated approval (8)
Adcomms (14)
Allergies (63)
Alliances (21763)
ALS (91)
Alzheimer's disease (934)
Antibody-drug conjugate (ADC) (140)
Approvals (5840)
Artificial intelligence (175)
Autoimmune disease (32)
Automation (7)
Bankruptcy (105)
Best Places to Work (4558)
BIOSECURE Act (6)
Biosimilars (64)
Biotechnology (231)
Bladder cancer (79)
Brain cancer (30)
Breast cancer (227)
Cancer (2132)
Cardiovascular disease (168)
Career advice (136)
Career pathing (2)
CAR-T (158)
CDC (4)
Cell therapy (422)
Cervical cancer (11)
Clinical research (42143)
Collaboration (784)
Company closure (2)
Compensation (421)
Complete response letters (27)
COVID-19 (1069)
CRISPR (70)
C-suite (306)
Cystic fibrosis (92)
Data (2515)
Denatured (13)
Depression (58)
Diabetes (192)
Diagnostics (1326)
Digital health (4)
Diversity (3)
Diversity, equity & inclusion (9)
Drug discovery (119)
Drug pricing (36)
Drug shortages (3)
Duchenne muscular dystrophy (161)
Earnings (30925)
Editorial (21)
Employer branding (4)
Employer resources (29)
Events (49988)
Executive appointments (567)
FDA (6960)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (684)
Gene editing (137)
Generative AI (12)
Gene therapy (358)
GLP-1 (436)
Government (1118)
Grass and pollen (2)
Guidances (142)
Healthcare (6604)
HIV (12)
Huntington's disease (30)
IgA nephropathy (44)
Immunology and inflammation (134)
Immuno-oncology (7)
Indications (29)
Infectious disease (1146)
Inflammatory bowel disease (133)
Inflation Reduction Act (9)
Influenza (26)
Intellectual property (109)
Interviews (18)
IPO (7321)
IRA (12)
Job creations (866)
Job search strategy (127)
Kidney cancer (8)
Labor market (15)
Layoffs (231)
Leadership (5)
Legal (1394)
Liver cancer (37)
Longevity (8)
Lung cancer (313)
Lymphoma (158)
Machine learning (12)
Management (7)
Manufacturing (233)
MASH (88)
Medical device (2623)
Medtech (2627)
Mergers & acquisitions (6413)
Metabolic disorders (531)
Multiple sclerosis (75)
NASH (13)
Neurodegenerative disease (115)
Neuropsychiatric disorders (34)
Neuroscience (1548)
NextGen: Class of 2025 (2021)
Non-profit (858)
Now hiring (26)
Obesity (248)
Opinion (110)
Ovarian cancer (91)
Pain (67)
Pancreatic cancer (96)
Parkinson's disease (160)
Partnered (9)
Patents (213)
Patient recruitment (174)
Peanut (39)
People (26112)
Pharmaceutical (46)
Pharmacy benefit managers (5)
Phase I (14884)
Phase II (19601)
Phase III (12373)
Pipeline (1550)
Policy (76)
Postmarket research (853)
Preclinical (6321)
Press Release (30)
Prostate cancer (96)
Psychedelics (44)
Radiopharmaceuticals (221)
Rare diseases (407)
Real estate (1432)
Recruiting (12)
Regulatory (9128)
Reports (19)
Research institute (945)
Resumes & cover letters (17)
Rett syndrome (10)
RNA editing (15)
RSV (12)
Schizophrenia (91)
Series A (124)
Series B (92)
Service/supplier (1)
Sickle cell disease (56)
Special edition (15)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1992)
State (1)
Stomach cancer (5)
Supply chain (27)
Tariffs (16)
The Weekly (51)
Vaccines (282)
Venture capital (44)
Weight loss (134)
Women's health (18)
Worklife (2)
Date
Today (28)
Last 7 days (225)
Last 30 days (1224)
Last 365 days (18511)
2025 (12759)
2024 (20549)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11739)
2017 (13746)
2016 (11840)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7533)
2011 (7614)
2010 (7428)
Location
Africa (151)
Alabama (57)
Alaska (2)
Arizona (59)
Arkansas (5)
Asia (17764)
Australia (3006)
California (5386)
Canada (1479)
China (545)
Colorado (196)
Connecticut (204)
Delaware (158)
Europe (38117)
Florida (675)
Georgia (170)
Hawaii (2)
Idaho (16)
Illinois (308)
India (18)
Indiana (119)
Iowa (7)
Japan (135)
Kansas (71)
Kentucky (6)
Louisiana (4)
Maine (11)
Maryland (596)
Massachusetts (4271)
Michigan (89)
Minnesota (201)
Mississippi (3)
Missouri (26)
Montana (14)
Nebraska (4)
Nevada (25)
New Hampshire (15)
New Jersey (1303)
New Mexico (12)
New York (1390)
North Carolina (690)
North Dakota (6)
Northern California (2476)
Ohio (143)
Oklahoma (9)
Oregon (21)
Pennsylvania (996)
Puerto Rico (7)
Rhode Island (24)
South America (209)
South Carolina (6)
Southern California (2095)
Tennessee (31)
Texas (678)
United States (18094)
Utah (76)
Virginia (113)
Washington D.C. (36)
Washington State (450)
West Virginia (1)
Wisconsin (27)
274,611 Results for "pluristem therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
Pluristem Therapeutics Inc., a leading biotechnology company, announced topline results from its multinational double-blind, placebo-controlled phase III study.
July 13, 2022
·
8 min read
Press Releases
NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer’s Treatment
June 16, 2025
·
4 min read
Business
Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture
Pluristem Therapeutics Inc. and Tnuva Group jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat.
March 8, 2022
·
7 min read
Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform
Leading biotechnology company Pluristem Therapeutics Inc. and Israel’s largest food producer Tnuva Group announced the closing of its landmark collaboration to develop, manufacture and commercialize cell-based products for the food industry.
February 24, 2022
·
5 min read
Pluristem CEO Issues Shareholder Update - Sep 22, 2021
Pluristem Therapeutics Inc., a leading biotechnology company, issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay.
September 22, 2021
·
7 min read
Press Releases
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
September 4, 2025
·
4 min read
Press Releases
Nektar Therapeutics to Participate in Two Investor Conferences in September 2025
September 4, 2025
·
2 min read
Press Releases
vTv Therapeutics to Participate in Upcoming September 2025 Investor Conferences
September 4, 2025
·
1 min read
Press Releases
CRISPR Therapeutics to Participate in Upcoming September 2025 Investor Conferences
September 3, 2025
·
1 min read
Press Releases
UPDATE -- vTv Therapeutics to Participate in Upcoming September 2025 Investor Conferences
September 4, 2025
·
1 min read
1 of 27,462
Next
